Skip to main content

Dr. House Receives STTR Grant

October 1, 2020

Dr. House, who is Principal Investigator, has been recognized as an expert in the uterine cervix.

A headshot of Dr. Michael House

Dr. House was awarded a grant through the highly competitive Federal Small Business Technology Transfer (STTR) Program. These grants are awarded to domestic small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for commercialization. Dr. House’s grant is entitled “A novel device for cervical insufficiency in pregnant women.” Cervical insufficiency is a significant pregnancy complication leading to preterm birth, as well as long-term morbidity and mortality of newborn infants. This STTR will develop an innovative medical device to treat cervical insufficiency with improved efficacy and fewer complications compared with traditional cerclage. An effective, alternate treatment for cervical insufficiency will have a significant impact on clinical efforts to prevent preterm birth where cervical insufficiency is the cause. The research in this project is supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under award number R41HD102268. Read more about Dr. House’s research focus here.

Press Releases
Dr. Michael House Receives Grand Prize for Novel Device To Prevent Preterm Birth
Dr. Michael House Receives Grand Prize for Novel Device to Prevent Preterm Birth.
Articles
Prinicipal Investigator, Michael House, MD, Receives an SMFM/ABOG Bridge Grant
Michael House, MD, has been recognized as an expert in the uterine cervix, has received an SMFM/ABOG Bridge Grant entitled “Novel tools for studying cervical function and dysfunction during pregnancy.”
Press Releases
Research Grant | Newborns With NAS
Tufts Medical Center and Prapela have been awarded a joint $2.5 million grant from the National Institute on Drug Abuse to help advance the development hospital bassinets for the treatment of newborns diagnosed with Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS).

Be among the first to know

Enjoy the latest health updates from Tufts Medicine by signing up for our e-newsletter today.

Jump back to top